- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT05671133
Wirksamkeit und Implementierung eines klinischen Entscheidungsunterstützungssystems zur Verhinderung von suizidalem Verhalten
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This study is designed to test the effects of providing emergency department (ED) clinicians with enhanced information about their patients' risk of a suicide attempt in the 6-months after leaving the ED. The study will be conducted in five EDs. The primary study will be conducted in four EDs within Mass General Brigham (MGB): Massachusetts General Hospital (MGH), MGB-Salem, Brigham and Women's Hospital (BWH), and Brigham and Women's Faulkner Hospital (BWFH). The investigators propose to enroll 4,000 participants over the study period and to provide the treating clinician with a risk score for a randomly selected half of those 4,000 participants. The primary outcome will be rate of suicide attempts over the next 6-months. It is anticipated that provision of this risk score will change clinician decision-making, leading clinicians to be more likely to hospitalize high-risk patients and less likely to hospitalize low-risk patients. A smaller (N=250) pilot implementation study has been added in a new non-MGB ED at Cambridge Health Alliance (CHA).
The primary study will enroll 4,000 patients presenting to the ED at MGH MGB-Salem, BWH, and BWFH. Study inclusion criteria include presentation to the ED, adult status (≥18 years-old), and ability to provide an email address.
Exclusion criteria include the presence of any factor that impairs an individual's ability to comprehend and effectively participate in the study, including an inability to speak or write English fluently, the presence of gross cognitive impairment due to florid psychosis, intellectual disability, dementia, acute intoxication, or the presence of extremely agitated or violent behavior. These broad inclusion criteria maximize the clinical applicability of results while the exclusion criteria ensure the ethical principle of respect for persons.
According to prior studies in the MGB system, investigators anticipate the MGB sample will be about 73% White/European American, 9% African-American, 4% Asian American, and the remainder of other or mixed ethnicity. The implementation study will enroll 250 patients presenting to the ED at CHA and will have the same inclusion/exclusion criteria as the primary study. Based on recent numbers reported in the CHA 2021 Annual Report, it is anticipated that the CHA sample will be about 37% White/European American, 16% African- American, 9% Asian American, and the remainder of other or mixed ethnicity.
Study Research Assistants (RAs) will use well-established protocols of reviewing patients presenting to the ED, where investigators have been conducting IRB approved research on the prediction of suicidal behavior for >15 years. RAs will first consult potentially eligible patients' assigned clinician to obtain their permission to approach the patient to briefly describe the study and ask if they are interested in learning more about it. Only those patients determined to meet the inclusion/exclusion criteria will be approached. To further ensure communication between the research and clinical team, investigators will give a presentation about the study to the ED clinical teams before starting recruitment and at regular intervals throughout the award period. RAs will obtain written informed consent from participants (using REDCap, described below) while in the ED, and administer a baseline self-report assessment battery (on an iPad). Contact information (including the full name, phone number, and if available, email address for both the participant and a collateral contact for emergency situations) will be collected via secure REDCap data collection surveys at baseline, and with participants' permission, select health data (e.g., readmission for a suicide attempt over the next 6 months) will be extracted from the EHR (and stored in a de-identified database). Participants will receive an email-based survey to assess the receipt of treatment and the presence of a suicide attempt at 1-month and 6-months after their ED visit. Participants will receive financial incentives for each survey completed.
In the primary study, after completing a brief baseline assessment, participants will be randomly assigned (1:1) to have their clinician receive a predicted probability that this patient will make a suicide attempt after leaving the ED. There is no intervention with the patient themselves. Investigators hypothesize that clinicians receiving this evidence-based prediction score will be more likely to hospitalize high-risk patients and less likely to hospitalize low-risk patients and that this will lead to a decrease in the rate of suicide attempts in the experimental condition relative to the control condition. The primary endpoint in this study is suicide attempt during the six months post-randomization. Suicide attempts will be measured using two methods: (a) self-report surveys and (b) documentation in the EHR during the follow-up period. Self-report questions about suicide attempts will be those from the Self-Injurious Thoughts and Behaviors Interview (SITBI), a widely used measure of suicidal thoughts and behaviors with strong reliability and validity and one of the measures recommended in the PhenX toolkit. Investigators also will examine all new medical records during the 6-months following each participant's index ED visit to determine if the participant revisited the hospital due to suicide ideation or suicide attempt during the follow-up period. This approach has been used in prior studies to measure such outcomes. In prior work in the APS we have found high agreement between self-reports on the SITBI and the documentation of suicide attempts in electronic medical records (K=.84). Secondary endpoints are suicide attempt within 1-month post-randomization. Additional exploratory hypotheses are: (1) among patients estimated by the model to be high-risk, clinicians of patients in the experimental condition will be more likely to recommend hospitalization than clinicians of patients in the control condition; (2) among patients estimated to be at intermediate risk, clinicians of patients in the experimental condition are (a) less likely to recommend hospitalization and (b) more likely to recommend partial hospitalization compared to clinicians of patients in the control condition, and (3) among patients estimated to be at low risk, clinicians of patients in the experimental condition are more likely to discharge to home than clinicians of patients in the control condition. Investigators will additionally investigate the mediating role of clinician choice on the association between the intervention and patient outcomes using mediation analysis.
Studientyp
Einschreibung (Geschätzt)
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
- Name: Matthew Nock, PhD
- Telefonnummer: 617-496-4484
- E-Mail: nock@wjh.harvard.edu
Studieren Sie die Kontaktsicherung
- Name: Amy Ahn, PhD
- E-Mail: yahn@fas.harvard.edu
Studienorte
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Rekrutierung
- Massachusetts General Hospital
-
Kontakt:
- Matthew Nock
- Telefonnummer: 6174964484
- E-Mail: nock@wjh.harvard.edu
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Beschreibung
Einschlusskriterien:
- Alter 18 Jahre oder älter
- Vorstellung beim psychiatrischen Notdienst
Ausschlusskriterien:
- Unfähigkeit, die Studienverfahren zu verstehen und eine Einverständniserklärung abzugeben, wie z. B. bei Personen mit grober kognitiver Beeinträchtigung (einschließlich florider Psychose), geistiger Behinderung, Demenz, akuter Vergiftung
- Vorhandensein von gewalttätigem oder extrem aufgeregtem Verhalten
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Single
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Kein Eingriff: Kontrolle
Der Arzt des Patienten erhält kein Clinician Decision Support Tool (Pflege wie gewohnt)
|
|
|
Experimental: Experimental
Investigators will use previously developed EHR-derived machine- learning-based model to generate predicted probability risk scores of 1-month suicide attempt for each patient.
The EHR-derived risk score will be combined with the patient self-report data (initially from the 20-question screener) to generate composite predicted risk scores (based on the most updated ML model developed by investigators via the ensemble ML Super Learner [SL] method) for the patient within minutes of the patient completing the self-report survey.
Risk scores will be provided to the clinician while the patient is in the ED.
This feedback includes information about the patient's relative risk compared to other psychiatric patients seen in the ED and the risk factors contributing to this level of risk.
|
Clinician Decision Support Tool, das Informationen über die statistische Wahrscheinlichkeit eines Suizidversuchs des Patienten im nächsten Monat liefert
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Suicide attempt
Zeitfenster: 6-months
|
The primary endpoint is the occurrence (0,1) of a suicide attempt during the 6 months following randomization.
The outcome will be measured as a single binary variable, indicating whether a participant experienced at least one suicide attempt during the follow-up period.
This outcome will be ascertained using participant self-report and EHR documentation.
Self-reported suicide attempts will be assessed using questions from the Self-Injurious Thoughts and Behaviors Interview (SITBI), a widely used measure of suicidal thoughts and behaviors with strong reliability and validity and one of the measures recommended in the PhenX Toolkit.
EHR review will further identify documented suicide attempts during follow-up.
Information from both sources will be used to determine a single outcome value for each participant.
The singular outcome measure is the occurrence of at least one suicide attempt during follow-up (Yes/No; 0,1) as identified by either source (self-report or EHR).
|
6-months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Selbstmordversuch
Zeitfenster: 1 Monat
|
Sekundäre Endpunkte sind Selbstmordversuch (unter Verwendung derselben Bewertungsmethoden wie der primäre Endpunkt) innerhalb von 1 Monaten nach der Strandomisierung und werden auch unter Verwendung von zwei Probentests von Proportionen bewertet.
|
1 Monat
|
Mitarbeiter und Ermittler
Sponsor
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Geschätzt)
Studienabschluss (Geschätzt)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2022P002689
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
IPD-Sharing-Zeitrahmen
Art der unterstützenden IPD-Freigabeinformationen
- STUDIENPROTOKOLL
- SAFT
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Produkt, das in den USA hergestellt und aus den USA exportiert wird
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .